• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

endo

  1. A Slow Death to PAR & Endo

    We told you that Huntsville would prevail in the end. This is what happens when you bring on a leadership team that lies and has shady practices. The Ghost of Huntsville.
  2. Trump to Come to PAR Huntsville Site

    Donald Trump's administration has announced he will make a visit to the PAR Huntsville Site while in town to support Luther Strange for Senate. The sole purpose of the visit is to discuss the possibilities of keeping the site open to retain jobs in Alabama. There have been talks that Donald...
  3. Lab and manufacturing celebration in the north

    Tomorrow, as we watch our little brothers and sisters fall, I declare a day of orgy in the facility! I know our girls hit 4, maybe 5, at best, so feel free to take up with more than one. 1st. The anal train, where all the guys lined up and centipeded around the lab with the mouths affixed...
  4. PAR South Will Be Sold Off

    PAR South to be sold off. At least that's what it's looking like for everyone down in Alabama. Executive leadership does not understand how to handle high volume products. They fired a sales force to protect the ones at the PAR North facilities and volume is down 60% on every product. That...
  5. Naptara

    Can anyone shed some light on this division (Endo/Naptara)? I see a few positions open and wondering if they are due to expansion or people leaving/being fired?